MFN deals, Lilly takeout, FDA pick Overton — a BioCentury podcast

• MFN drug pricing risk — Medicare pricing demonstrations could trigger litigation, delays or reversal while creating collateral damage for companies unable to secure most-favored-nation deals

• Lilly's acquisition strategy — Lilly's thirteenth takeout of the year shows sustained willingness to spend on pipeline building, including immunology platforms with potential differentiation in autoimmune and allergic disease...